Please login to the form below

Not currently logged in
Email:
Password:

Eisai cuts US workforce by 20 percent

Eisai, the US pharmaceutical operation of Japan's Eisai, plans to cut its workforce by about 20 per cent across all US functions

Eisai, the US pharmaceutical operation of Japan's Eisai, plans to cut its workforce by about 20 per cent across all US functions, laying off approximately 600 workers by the start of next month.

"This organisational restructuring supports Eisai's global mid-term strategic plan for FY2011-2015, which seeks to transform Eisai's business into a more efficient and focused organisation to better serve its human healthcare mission," says the company.

Eisai intends to invest the cost-savings largely in accelerating its oncology portfolio and launching new neuroscience assets.

Eisai said it does not plan to close any of its main offices or facilities. The company's US operations include R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina.

The announcement of the layoffs comes on the heels of Eisai's decision last month to delay the submission of US, European and Japanese marketing applications for its investigational sepsis drug eritoran due to disappointing preliminary results from a global phase III trial. The company had been aiming to submit the applications by March 31, but a preliminary analysis of data showed the drug was not effective in reducing 28-day all-cause mortality in patients with severe sepsis.

The company is also struggling to replace profits lost when the blockbuster Alzheimer's disease drug Aricept (donepezil) lost its patent protection late last year.

9th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics